A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms KeyLargo
- 04 Jun 2024 Results (n=25) of an ultra-sensitive liquid biopsy performed to detect ctDNA levels in the FFPE tumor samples of metastatic esophagogastric cancer patients who showed a complete or partial response in this study, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2024 Results of novel prognostic and predictive circulating protein biomarkers, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results of a retrospective analysis (n=36) using plasma samples from this trial focusing on tumor-informed ctDNA approach as a tool for longitudinal disease monitoring and dynamic tumor evolution presented at the 59th Annual Meeting of the American Society of Clinical Oncology